Abstract 241P
Background
Cabozantinib is approved in first-line metastatic renal cell carcinoma (mRCC), as a single agent and in combination with nivolumab. In real-world setting, only a miniscule proportion of Indian patients with mRCC manage to afford nivolumab, and majority of the patients end up receiving first-line cabozantinib monotherapy. Unfortunately, even though cabozantinib has been approved for long time, there is no published data from India regarding the experience of first-line cabozantinib in mRCC.
Methods
From February 2022 to August 2023, consecutive patients of mRCC who were treated with first-line cabozantinib monotherapy, were prospectively followed. Response rates, survival outcomes and toxicity were analyzed for patients who received at least 3 months of cabozantinib. The adverse events were classified based on the CTCAE v 4.0.
Results
Of the 21 mRCC patients, 18 (86%) were males. Median age at diagnosis was 56 years (range: 35-72); and 20 (95%) patients had clear cell histology. Most common site of metastasis was lungs (n=14) followed by bone (n=12), non-regional lymph nodes (n=6) and liver (n=3). Two patients had favorable risk disease, whereas 15 had intermediate risk and 4 had poor risk disease according to IMDC risk criteria. Dose reductions due to toxicity were required in 8 (38%) patients. At initial evaluation (3 months after treatment initiation), 20 patients had disease control (partial response in 3 and stable disease in 17 patients), while one had progression of disease. At a median follow-up of 11.5 months (range: 3–19); median progression free survival was not reached (total number of progression events = 5) and all patients were surviving. Toxicities of cabozantinib were grade 1 or 2 in 12 patients and grade 3 or 4 in 7 patients. The most frequent grade 3-4 adverse events were diarrhea (n=3, 14.3%), hypertension (n=3, 14.3%), palmar-plantar erythrodysesthesia syndrome (n=2, 9.5%), stomatitis (n=1, 4.8%), and hepatic transaminitis (n=1, 4.8%).
Conclusions
Cabozantinib is a viable first-line option for Indian patients with mRCC. Keeping in mind the toxicity profile and need for dose reduction; starting with 40 mg daily dose and careful tailoring as per tolerance, seems to be practically more feasible in our setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract